STEP THERAPY POLICY

POLICY: Antiepileptics – Oxtellar XR, Trileptal Step Therapy Policy
- Trileptal® (oxcarbazepine tablets and oral suspension – Novartis, generic)
- Oxtellar XR® (oxcarbazepine extended-release tablets – Supernus)

REVIEW DATE: 03/23/2022

OVERVIEW

Oxcarbazepine tablets and oral suspension are indicated for use as monotherapy or adjunctive therapy in the treatment of **partial seizures** in adults, as monotherapy in the treatment of partial seizures in patients ≥ 4 years of age with epilepsy, and as adjunctive therapy in the treatment of partial seizures in patients ≥ 2 years of age.[1] Oxtellar XR is indicated for the treatment of partial seizures in patients ≥ 6 years of age.[2]

Oxcarbazepine is an antiepileptic drug (AED) available in immediate- and extended-release formulations.[1,2] Oxtellar XR administered as a once daily dose is not bioequivalent to the same total dose of the immediate-release formulation given twice daily at steady state.[2]

POLICY STATEMENT

This program has been developed to encourage the use of a Step 1 Product prior to the use of a Step 2 Product. If the Step Therapy rule is not met for a Step 2 Product at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration.

Automation: A patient with a of one Step 1 Product within the 130-day look-back period is excluded from Step Therapy.

Step 1: generic oxcarbazepine tablets, generic oxcarbazepine oral suspension

Step 2: Oxtellar XR, Trileptal tablets and oral suspension

CRITERIA

1. If a patient has tried one Step 1 Product, approve a Step 2 Product.

2. No other exceptions are recommended.

REFERENCES

1. Trileptal® tablets and oral suspension [prescribing information]. East Hanover, NJ: Novartis; January 2019.
2. Oxtellar XR® extended-release tablets [prescribing information]. Rockville, MD: Supernus; December 2018.